CN102813660A - External medicine for treating skin eczema - Google Patents
External medicine for treating skin eczema Download PDFInfo
- Publication number
- CN102813660A CN102813660A CN2012103381186A CN201210338118A CN102813660A CN 102813660 A CN102813660 A CN 102813660A CN 2012103381186 A CN2012103381186 A CN 2012103381186A CN 201210338118 A CN201210338118 A CN 201210338118A CN 102813660 A CN102813660 A CN 102813660A
- Authority
- CN
- China
- Prior art keywords
- medicine
- external medicine
- eczema
- skin
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an external medicine for treating skin eczema, belonging to the field of medicine. The invention aims to provide an external medicine for treating skin eczema, which combines multiple medicines and has an obvious curative effect on skin eczema. The active ingredient of the external medicine disclosed by the invention consists of the following raw materials: chloramphenicol powder, dexamethasone, chlortrimeton, enhanceparaben, vaseline, glycerol, stearic acid, triethanolamine, liquid paraffin and distilled water. The external medicine disclosed by the invention can quickly relieve and even cure the symptom of a patient so as to avoid the pain of the patient, is a good method for treating eczema and deserves popularization and application. The treatment effect is realized while the skin hurt caused by the medicine is reduced. The external medicine has the effects of diminishing inflammation, reliving itching and resisting allergy, takes an effect quickly, prevents toxic side effects, and is convenient to use, thereby being a relatively ideal ointment formula for treating allergic diseases.
Description
Technical field
The invention belongs to field of medicaments.
Background technology
Skin eczema is a kind of common allergy, non-infectious, anaphylaxis epidermis inflammation, and the epidermis that is caused by multiple internal and external factor and the inflammatory skin of high dermis are sick, and it is generally acknowledged with allergy has certain relation.Its clinical manifestation has characteristics such as symmetry, exudative, itching skin disease, pleomorphism and recurrent.Eczema is a kind of dermatosis of easy relapse, treatment need special-purpose medicine as, also be a kind of allergic inflammation dermatoses with the erythra multiformity, be symmetrically distributed, violent pruritus shows effect, is prone to develop into the chronic characteristic that is repeatedly.Can betide any position of any age, but recur or aggravate the winter of being everlasting the tendency of oozing out arranged any season, the chronic course of disease is prone to outbreak repeatedly.
Summary of the invention
The objective of the invention is to adopt multiple drug regimen to use, skin eczema is had a kind of external used medicine of treating skin eczema evident in efficacy.
The present invention processes the raw materials of effective components weight portion and consists of:
Chlormycetin powder 83---117 dexamethasone 2.5---3.5 chlorphenamine 14---19
Nipagin ester 33---47 vaseline 4167---5833 glycerol 167----233
Stearic acid 2500---3500 triethanolamine 666---933 liquid paraffin 417---583
Distilled water 417---583.
The present invention is the symptom even the healing of reduction of patient rapidly, makes the patient remove misery from.Be the good method of treatment eczema, be worth of widely use.Promptly reach therapeutic effect, reduce medicine again skin lesion.Have antiinflammatory, antipruritic, anti-allergic effects, and instant effect, have no side effect.Easy to use, be a kind of medical ointment prescription of comparatively ideal treatment anaphylactic disease.
The specific embodiment
The present invention processes the raw materials of effective components weight portion and consists of:
Chlormycetin powder 83---117 dexamethasone 2.5---3.5 chlorphenamine 14---19
Nipagin ester 33---47 vaseline 4167---5833 glycerol 167----233
Stearic acid 2500---3500 triethanolamine 666---933 liquid paraffin 417---583
Distilled water 417---583.
With dexamethasone, chlorphenamine, chloromycetin with mortar porphyrize (170 order); With joining in the water (distilled water, glycerol) behind a small amount of (1:5) dissolved in distilled water; Nipalgin (powdery) is joined in the oil phase (vaseline, stearic acid, liquid paraffin) to boil (110 ~ 120 ℃), and profit is biphase to be heated respectively and keeps 70 ~ 80 ℃, under stirring condition, respectively oil phase is slowly joined aqueous phase; And solidify with adding with being stirred to by same direction, promptly get.
Embodiment 1
The present invention processes the raw materials of effective components weight portion and consists of:
Chlormycetin powder 83 dexamethasone 2.5 chlorphenamines 14
Nipagin ester 33 vaseline 4167 glycerol 167
Stearic acid 2500 triethanolamine 666 liquid paraffin 417
Distilled water 417.
With dexamethasone, chlorphenamine, chloromycetin with mortar porphyrize (170 order); With joining in the water (distilled water, glycerol) behind a small amount of (1:5) dissolved in distilled water; Nipalgin (powdery) is joined in the oil phase (vaseline, stearic acid, liquid paraffin) to boil (110 ~ 120 ℃), and profit is biphase to be heated respectively and keeps 70 ~ 80 ℃, under stirring condition, respectively oil phase is slowly joined aqueous phase; And solidify with adding with being stirred to by same direction, promptly get.
Embodiment 2
The present invention processes the raw materials of effective components weight portion and consists of:
Chlormycetin powder 100, dexamethasone 3, chlorphenamine 16.8, Nipagin ester 40, vaseline 4500, glycerol 200, stearic acid 3000, triethanolamine 800, liquid paraffin 500, distilled water 500.
Method for preparing is identical with embodiment 1.
Embodiment 3
The present invention processes the raw materials of effective components weight portion and consists of:
Chlormycetin powder 83---117 dexamethasone 2.5---3.5 chlorphenamine 14---19
Nipagin ester 33---47 vaseline 4167---5833 glycerol 167----233
Stearic acid 2500---3500 triethanolamine 666---933 liquid paraffin 417---583
Distilled water 417---583.
Method for preparing is identical with embodiment 1.
Dexamethasone is a glucocorticoid medicine.It has antiinflammatory, antiallergic and antitoxic action.Sick for the inflammatory skin of a lot of types and different reasons, he for example can promptly alleviate and eliminate symptoms such as pruritus.
Chlormycetin powder is the antimicrobial component of these article, is a kind of broad-spectrum antibacterial agent.But get in the bacterial cell through fat-soluble disperse, mainly act on the ribosomal 50s subunit of antibacterial 70s, suppress transpeptidase, the growth of peptide chain is obstructed, suppressed the formation of peptide chain, thereby stop proteinic synthetic.Also be bactericidal action during high concentration or to the extremely sensitive antibacterial of these article.Can play a role to following antibacterial: enterobacteriaceae lactobacteriaceae (like escherichia coli, clostridium perfringen, klebsiella, Salmonella etc.) and anthrax bacillus, streptococcus pneumoniae, streptococcus, listeria spp, staphylococcus etc.Chlamydia, leptospira, rickettsia are also responsive to these article.Anaerobe such as clostridium tetani, bacillus perfringens, actinomycetes and lactobacillus, Fusobacterium etc.
Chlorphenamine is the H1 receptor antagonist; The effect of histamine H1-receptor on the stronger competitiveness blocking-up allergy target cell is arranged; Antagonism through to the H1 receptor plays anti-allergic effects; Except, also have the effect of anti-M cholinoceptor, so can occur symptoms such as xerostomia, constipation, sputum retrogradation, nasal mucosa drying after taking medicine.This medicine also has the effect of certain inhibition maincenter in addition, tool sedation, the sleepy untoward reaction after therefore can occurring taking medicine.Forbid after drinking taking.
Nipagin ester is a kind of milky to a yellowish-brown powder, odorless, tasteless, very easily moisture absorption caking.It is one type of non-ionic surface active agent of sucrose and fatty acid-based be combined into.Edible is harmless.It is a kind of emulsion stabilizer efficiently.But the cell membrane of Nipagin ester destroy microorganisms has low toxicity, efficient, characteristics such as consumption is few, antimicrobial spectrum is wide, is the antiseptic safely and effectively that adopts in the world, is widely used in industries such as food, cosmetics and medicine.Main sterilization antiseptic as organic synthesis, food, cosmetics, medicine.
Vaseline is a kind of mineral wax, can form protecting film one in skin surface, makes the moisture of skin be difficult for evaporating lost; And it is extremely water insoluble, can therefore have good moistening effect for a long time attached on the skin; Very being fit to dry skin and using, is the extraordinary articles for use of preserving moisture.Also has the effect of removing scar.The vaseline nonirritant, stable not perishable, also be difficult for causing human body responsive, the most suitable spice, the ethanol people hypersensitive that general skin moistening product is added.Its shortcoming is too greasy, only is fit to use in extremely dried skin or bone-dry winter.Youngster for inclined to one side oily skin then is not suitable for, and causes acne and acne etc. because can block pore.
Glycerol is the transparent thick liquid of appearance colorless, odorless, tasteless, have hygroscopicity, humectation property, a property of softening, extremely show and absorb airborne moisture, the moisturizing effect is very good, is commonly used to do the interpolation raw material of cosmetics.In order to produce various preparations, solvent, hygroscopic agent, antifreezing agent and sweeting agent, ingredients externally-applied ointment or suppository etc.
Stearic acid is a kind of main component that constitutes the animal and plant oils and fats.These article are nontoxic, in skin care item, play emulsification, stablize pure white mastic thereby it is become.In cosmetics industry, be to make the indispensable raw material of general emulsifying goods, can be used for products such as pharmaceutical preparation, preparation vanishing cream, cold cream, foundation cream, ointment, soap and suppository.
Triethanolamine is as plasticizer, nertralizer, lubricant additive or anticorrosive and textile, the humidizer of cosmetics and the dispersant of dyestuff, resin etc.It can neutralize triethanolamine with CP-940, thus the effect that reaches thickening and preserve moisture.Be used to wash the agent raw material; The cosmetics raw material; Skin care item, cosmetic material.
Liquid paraffin has low irritability and good closure, and the effect of the water evaporates that intercepts skin is arranged, and uses so often be taken as in the medium skin care item of the emulsion of being everlasting or cream along sliding wetting agent.It also has good oil-soluable property, so also can appear at makeup removing oil or the makeup removing Ruzhong usefulness as makeup removing.The substrate that can be used as ointment, liniment and cosmetics.
Drug therapy skin eczema of the present invention carries out 425 routine clinical observations, and wherein 305 examples are organized in treatment, matched group 120 examples:
1 data and method
1.1 physical data seminar is 305 routine eczema patients, clinical manifestation all meets the diagnostic criteria of eczema, wherein male 192 examples, women 113 examples, 1 years old-57 years old age, course of disease average out to 3 days-3 months.Matched group 120 routine eczema patients, male 75 examples, women 45 examples.No difference of science of statistics in patient age, the course of disease and the clinical manifestation.
1.2 Therapeutic Method treatment group gives external ointment of the present invention and is applied in the affected part, once a day.Matched group gives momestasone furoate emulsifiable paste (Fu Lin, Hubei Hengan Pharmaceutical Co., Ltd) and is applied in the affected part, once a day.Be a week course of treatment, the patient is not associating external and whole body use antihistaminic, glucocorticoid and immunosuppressant during medication.
1.3 before the curative effect determinate standard treatment and after 1 week of treatment, by 4 grades of point systems, promptly 0=does not have, 1=is light, 2=moderate, 3=severe, (erythema, pimple, erosion, ooze out) carried out objective evaluation to patient's symptom (pruritus) and sign respectively.Total mark * 100% before therapeutic index (%)=(total mark before the treatment-treatment back total mark)/treatment.Recovery from illness descends>=95% for therapeutic index; Produce effects is that therapeutic index descends 60%～94%; Effectively descend 20%～59% for therapeutic index; Invalidly be that therapeutic index descends<20%.Recovery from illness adds up to effective percentage with the percentage ratio of produce effects example number.
1.4 the statistical procedures SPSS software, the relatively application X 2 test of rate, < 0.05 has statistical significance for difference to P.
Table 1 comprehensive therapeutic effect relatively
Two groups of comprehensive therapeutic effects compare, and the obvious effective rate of treatment group and total effective rate all are significantly higher than matched group, and difference has statistical significance (x
2=5.8, P 0.05)
Untoward reaction treatment group has no adverse reaction.
Claims (1)
1. external used medicine of treating skin eczema is characterized in that: wherein process the raw materials of effective components weight portion and consist of:
Chlormycetin powder 83---117 dexamethasone 2.5---3.5 chlorphenamine 14---19
Nipagin ester 33---47 vaseline 4167---5833 glycerol 167----233
Stearic acid 2500---3500 triethanolamine 666---933 liquid paraffin 417---583
Distilled water 417---583.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103381186A CN102813660A (en) | 2012-09-13 | 2012-09-13 | External medicine for treating skin eczema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103381186A CN102813660A (en) | 2012-09-13 | 2012-09-13 | External medicine for treating skin eczema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102813660A true CN102813660A (en) | 2012-12-12 |
Family
ID=47298345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103381186A Pending CN102813660A (en) | 2012-09-13 | 2012-09-13 | External medicine for treating skin eczema |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102813660A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287742A (en) * | 2015-10-29 | 2016-02-03 | 广州赛莱拉生物基因工程有限公司 | Ointment capable of controlling mosquito bite and preparation method thereof |
| CN105395593A (en) * | 2015-12-09 | 2016-03-16 | 广州赛莱拉生物基因工程有限公司 | Itching relieving ointment containing folium artemisiae argyi extract and preparation method thereof |
| CN106421765A (en) * | 2016-11-17 | 2017-02-22 | 郑州郑先医药科技有限公司 | Plaster for curing skin itch |
| CN106492219A (en) * | 2016-11-30 | 2017-03-15 | 郑州仁宏医药科技有限公司 | A kind of Western medicine compound for treating skin eczema and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126592A (en) * | 1995-01-13 | 1996-07-17 | 郭景维 | Baifuping cream for dermatosis |
| CN1157137A (en) * | 1996-02-14 | 1997-08-20 | 牟广志 | Cream for curing eczema |
| CN1190582A (en) * | 1998-03-23 | 1998-08-19 | 阎丽 | Antipruritic ointment for dermatitis |
-
2012
- 2012-09-13 CN CN2012103381186A patent/CN102813660A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126592A (en) * | 1995-01-13 | 1996-07-17 | 郭景维 | Baifuping cream for dermatosis |
| CN1157137A (en) * | 1996-02-14 | 1997-08-20 | 牟广志 | Cream for curing eczema |
| CN1190582A (en) * | 1998-03-23 | 1998-08-19 | 阎丽 | Antipruritic ointment for dermatitis |
Non-Patent Citations (2)
| Title |
|---|
| 崔福德: "《药剂学》", 29 February 2004, 人民卫生出版社 * |
| 徐军，等: "《药物大全》", 31 May 1995, 上海中医药大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287742A (en) * | 2015-10-29 | 2016-02-03 | 广州赛莱拉生物基因工程有限公司 | Ointment capable of controlling mosquito bite and preparation method thereof |
| CN105395593A (en) * | 2015-12-09 | 2016-03-16 | 广州赛莱拉生物基因工程有限公司 | Itching relieving ointment containing folium artemisiae argyi extract and preparation method thereof |
| CN106421765A (en) * | 2016-11-17 | 2017-02-22 | 郑州郑先医药科技有限公司 | Plaster for curing skin itch |
| CN106492219A (en) * | 2016-11-30 | 2017-03-15 | 郑州仁宏医药科技有限公司 | A kind of Western medicine compound for treating skin eczema and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2467759C2 (en) | Composition for local use and its applications | |
| JP2017226664A (en) | Pharmaceutical compositions comprising dgla, 15-ohepa and/or 15-hetre and use methods thereof | |
| WO2008140200A1 (en) | External compositions for the skin | |
| JP6666068B2 (en) | External composition | |
| KR20150056820A (en) | Topical compositions and methods of use | |
| US20120034320A1 (en) | Skin Penetration Composition | |
| CN102813660A (en) | External medicine for treating skin eczema | |
| CN115151241A (en) | CBD formulations and uses thereof | |
| KR20120058850A (en) | Compositions for the antiinflammatory and the antimicrobial activities | |
| TW201605444A (en) | Topical pharmaceutical or cosmetic compositions comprising octenidine dihydrochloride | |
| KR20150072797A (en) | Composition comprising high concentration caffeines | |
| US8932656B1 (en) | Oil blend for skin treatment | |
| EP3337512A1 (en) | A topical antiviral composition | |
| ZA202301109B (en) | Branched amino acid surfactants for use in healthcare products | |
| Mishra et al. | Topical antibiotics and semisolid dosage forms | |
| CN102166253A (en) | Oil-in-water type elsholtzia oil nano emulsion preparation and method for preparing same | |
| GB2481512A (en) | Topical formulation containing usnic acid/usnate and dimethyl isosorbide | |
| EP3313369B1 (en) | Emollient composition | |
| CN105168360A (en) | Compound plant extract liniment for treating acne and preparation method of compound plant extract liniment | |
| KR20150023607A (en) | Pharmaceutical composition comprising eriodictyol or its pharmaceutically acceptable salts as an active ingredient for preventing or treating contact dermatitis | |
| JP2020100576A (en) | External composition for skin | |
| KR20180135169A (en) | Composition for improving skin acne comprising quercetin and vitamin D | |
| US11318182B1 (en) | Plant extract for skin infections | |
| KR20140083425A (en) | Pharmaceutical composition comprising eriodictyol or its pharmaceutically acceptable salts as an active ingredient for preventing or treating contact dermatitis | |
| Li et al. | Dermatological pharmacology: topical agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121212 |